已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis

医学 内科学 中止 芳香化酶抑制剂 乳腺癌 肿瘤科 富维斯特朗 优势比 转移性乳腺癌 相伴的 危险系数 癌症 回顾性队列研究 胃肠病学 三苯氧胺 置信区间
作者
Azusa Taniguchi,Nobuyoshi Kittaka,Haruka Kanaoka,Satomi Nakajima,Yuri Oyama,Yukiko Seto,AI SOMA,Hiroki Kusama,Noriyuki Watanabe,Saki Matsui,Minako Nishio,Fumie Fujisawa,Takahiro Nakayama
出处
期刊:Anticancer Research [International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
卷期号:42 (12): 6027-6035 被引量:2
标识
DOI:10.21873/anticanres.16114
摘要

The efficacy of endocrine therapy combined with abemaciclib for hormone receptor-positive, HER2-negative metastatic breast cancer has been established through pivotal clinical trials. However, abemaciclib-induced liver injury (AILI) can be a cause for dose reduction or discontinuation. Therefore, it is critical to understand the risk factors for AILI.This retrospective study analyzed data from patients who had received abemaciclib combined with endocrine therapy for metastatic breast cancer as first- or second-line therapy at our hospital between December 2018 and October 2021. Relevant data were extracted from their medical records. Logistic regression analysis was performed to identify characteristics associated with AILI.Of the 52 eligible patients, 12 (23%) received an aromatase inhibitor (AI), and 40 (77%) received fulvestrant, concomitantly with abemaciclib. Fifteen (29%) of the patients developed liver injury after starting abemaciclib. Univariate analysis revealed the following risk factors for AILI: age ≥65 years (p=0.047), fatty liver disease (p=0.047), and concomitant use of an AI (p=0.002). Concomitant use of an AI was identified by multivariate analysis as an independent risk factor for AILI [odds ratio (OR)=10.23, 95% confidence interval (CI)=2.02-51.91, p=0.005].Concomitant use of an AI could be the most significant factor associated with increased risk of AILI. Future research on the mechanism by which the use of an AI plus abemaciclib can cause liver injury, and prospective studies to validate our findings regarding AILI risk factors, are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷静傲丝完成签到 ,获得积分10
2秒前
sigrid完成签到,获得积分10
3秒前
包子完成签到,获得积分10
4秒前
wbqdssl完成签到 ,获得积分10
8秒前
知足的憨人*-*完成签到,获得积分10
10秒前
momo应助桀桀桀采纳,获得10
10秒前
azhou176完成签到,获得积分10
11秒前
lucky完成签到 ,获得积分10
11秒前
丸子完成签到 ,获得积分10
11秒前
chestnut灬完成签到 ,获得积分10
12秒前
01259完成签到 ,获得积分10
12秒前
喜悦香薇完成签到 ,获得积分10
12秒前
15秒前
1230完成签到 ,获得积分10
16秒前
17秒前
Rondab应助科研通管家采纳,获得10
17秒前
领导范儿应助科研通管家采纳,获得10
17秒前
在水一方应助科研通管家采纳,获得10
17秒前
17秒前
白桦林泪完成签到,获得积分10
18秒前
yangzai完成签到 ,获得积分10
19秒前
21秒前
自然千山完成签到,获得积分10
21秒前
Augusterny完成签到 ,获得积分10
22秒前
YBR完成签到 ,获得积分10
23秒前
hellokitty发布了新的文献求助10
24秒前
白桦林泪发布了新的文献求助20
24秒前
24秒前
懵懂的冰凡完成签到,获得积分10
25秒前
知足的憨人丫丫完成签到,获得积分10
25秒前
不吃汉堡完成签到 ,获得积分10
28秒前
29秒前
29秒前
xx完成签到 ,获得积分10
31秒前
33秒前
乐乐乐乐乐乐应助duohao2023采纳,获得30
33秒前
34秒前
lizigongzhu发布了新的文献求助10
35秒前
36秒前
None完成签到 ,获得积分10
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989972
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256042
捐赠科研通 3270884
什么是DOI,文献DOI怎么找? 1805093
邀请新用户注册赠送积分活动 882256
科研通“疑难数据库(出版商)”最低求助积分说明 809216